Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: deubiquitinating enzyme inhibitors - MISSION Therapeutics

Next Previous
Drug Profile

Research programme: deubiquitinating enzyme inhibitors - MISSION Therapeutics

Alternative Names: DUB inhibitors - MISSION Therapuetics; Ubiquitin C-terminal hydrolase 1 inhibitors - MISSION Therapeutics; Ubiquitin-specific protease 10 inhibitors - MISSION Therapeutics; Ubiquitin-specific protease 30 inhibitors - MISSION Therapeutics; UCHL1 inhibitors - MISSION Therapeutics; USP10 inhibitors - MISSION Therapeutics; USP30 inhibitors - MISSION Therapeutics

Latest Information Update: 28 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MISSION Therapeutics
  • Class Antifibrotics; Antineoplastics; Neuroprotectants; Small molecules; Urologics
  • Mechanism of Action Deubiquitinating enzyme inhibitors; Ubiquitin-specific protease inhibitors; Usp30 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute kidney injury; Fibrosis; Idiopathic pulmonary fibrosis; Mitochondrial disorders; Mitochondrial myopathies; Neurodegenerative disorders
  • Discontinued Cancer; Ovarian cancer

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for preclinical development in Acute kidney injury in United Kingdom
  • 28 Jul 2024 No recent reports of development identified for preclinical development in Mitochondrial-myopathies in United Kingdom
  • 28 Dec 2022 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in United Kingdom

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top